Lite Strategy, Inc.
LITSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $65.3M | $48.8M | $40.7M | $34.8M | $1.2M |
| Operating income | −$17.5M | $14.5M | −$36.8M | −$75.5M | −$60.4M | −$24.5M |
| Net income | −$15.9M | $17.8M | −$32.0M | −$54.5M | −$41.3M | −$4.3M |
| Total assets | $18.3M | $41.4M | $120.8M | $177.8M | $174.1M | $209.7M |
| Total liabilities | $1.4M | $8.4M | $96.2M | $125.4M | $124.6M | $131.5M |
| Equity | $16.9M | $33.0M | $24.6M | $52.4M | $49.5M | $78.2M |
| EPS (diluted) | $-2.39 | $2.67 | $-4.78 | $-9.99 | $-0.60 | $-0.04 |
| Shares out. | 35.7M | 6.7M | 6.7M | 133.3M | 112.7M | 112.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −94.2%
- Return on assets
- −87.2%
- Return on capital (ROCE)
- −103.1%
- Liabilities / assets
- 7.4%
- Debt / equity
- 0.08×
- Book value / share
- $0.47
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- −189.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -59.27distress
- Accruals / assets
- 26.8%high accruals
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 17, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Citadel Advisors LlcPassive (13G)Feb 17, 2026
- Schornstein AlexanderPassive (13G)Dec 22, 2025
- Vanguard Group IncPassive (13G)Oct 31, 2025
- Anson Funds Management LpActivist (13D)Jul 24, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 77,104 | 1.0 | -19.1% |
| Apr 30, 2026 | 95,313 | 1.0 | +46.3% |
| Apr 15, 2026 | 65,145 | 1.0 | -29.3% |
| Mar 31, 2026 | 92,169 | 1.0 | -0.5% |
| Mar 13, 2026 | 92,664 | 1.0 | -23.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Results of operationsFeb 17, 2026
- Director / officer change · Shareholder voteFeb 12, 2026
- Director / officer changeDec 30, 2025
- Changed auditorDec 5, 2025
- Director / officer changeNov 18, 2025
- Director / officer change · Other material eventOct 30, 2025
- Unregistered equity saleSep 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.